Charles River's Insider CEO Bets on Modernization as Stock Jumps 50%

Charles River's first outsider CEO is betting a 50 percent stock rally can be sustained by modernizing the drug-development firm.

Charles River Laboratories' first CEO unrelated to its founder is betting a 50 percent stock rally on modernization, pushing AI-enabled pathology and a portfolio review to cut the time and cost of getting drugs into clinical trials.

"My mission on what we want to do with Charles River is really reducing the time it takes to get a drug into the clinic, because number one, the patients are waiting. Two, it's still costly," Birgit Girshick, chief executive officer of Charles River Laboratories, said.

Girshick, who started at the company as an executive assistant in Germany 35 years ago and held 16 or 17 roles across every division, took over as CEO on May 5 after a two-year transition in which predecessor James Foster let her effectively run the business. The stock has climbed more than 50 percent since her appointment. An agreement with Elliott Investment Management in May added four new directors to the board.

The transformation comes as Charles River, which provides drug-development services to pharmaceutical and biotech companies, faces pressure to accelerate timelines and cut costs. Girshick said the company is examining its portfolio to determine what to outsource and deepening ties with clients, with the goal of shortening the path from discovery to clinic.

Girshick made visiting the company's far-flung outposts one of her first priorities after taking over, rolling out her strategy to employees and listening to their challenges. "I want to roll out my strategy to them so that they know why we're doing things, why the urgency, what are we trying to accomplish and really what it means to them," she said.

Behind the strategy are less visible shifts. Girshick is emphasizing that her executive leadership is the first team, one that thinks across the whole business before functional responsibilities. She reinforced this by having her team swap roles at an off-site, so the head of communications, for instance, became the head of finance as they tackled issues. This differs from the Foster era, where issues went up to him and decisions came back down.

She is also working to incorporate outside perspectives, something she said is critical in a sector with few competitors. Outside CEOs, scientists and customers now visit, often sharing "a nibble that we didn't think about," she said.

AI Pathology and NGS Testing Expand

The modernization is already showing up in operations. Charles River has put in place an AI-enabled digital pathology system that promises faster turnaround times. The company has also expanded its Next-Generation Sequencing (NGS) testing capabilities, acquiring Pathoquest, a leader in NGS solutions for in vitro characterization and quality control testing of biopharmaceutical products.

In August, Charles River and Medigen Vaccine Biologics Corp. agreed to collaborate on the characterization and validation of a virus seed bank for Medigen's next-generation multivalent enterovirus vaccine. Charles River will use its NGS platforms to support Chemistry, Manufacturing, and Controls activities, helping align the program with global regulatory standards while supporting IND-enabling non-clinical studies.

The collaboration shows how Charles River is using its testing and non-clinical development capabilities to win work from vaccine and biotech developers. Kerstin Dolph, corporate senior vice president for global manufacturing at Charles River, said the company's experience in biologics, analytics and safety would help partners reach key milestones and advance the industry.

A 50% Rally Tests Durability

The stakes are high. Charles River's nearly 80-year history has seen just two prior CEOs, both tied to the founder. Girshick's appointment, combined with the Elliott agreement that added four directors, marks a shift toward greater board oversight and operational discipline. The question now is whether the 50 percent stock rally since May reflects durable change or early optimism.

This article is for informational purposes only and does not constitute investment advice.